IntuitionLabs
Suvoda IRT and RTSM consulting and integration services for pharmaceutical sponsors running complex global clinical trials

Suvoda IRT / RTSM Consulting & Integration for Clinical Trials

Implementation, AI enablement, and GxP validation for Suvoda IRT, RTSM, eConsent, and eCOA — purpose-built for oncology, rare disease, and complex global studies across the pharmaceutical industry.

Our Suvoda Services

We help sponsors and CROs get more out of their Suvoda investment — whether you are configuring your first study build, layering AI capabilities, or validating across a global oncology programme.

AI Innovation
AI & MCP Integration
Layer AI agents on Suvoda — supply forecasting, protocol amendment impact analysis, randomization analytics, and natural-language operational co-pilots with Claude and other LLMs via Model Context Protocol.
Explore AI integration
Compliance
GxP Validation
Validate Suvoda study builds for 21 CFR Part 11, EU Annex 11, GAMP 5, and ICH E6(R3) GCP. Risk-based protocols, UAT scripts, traceability, and inspection-ready evidence for every release.
View validation services
Implementation
Study Build & Integration
End-to-end Suvoda study builds including randomization schema, IP supply rules, eConsent and eCOA configuration, EDC and CTMS integration, depot connectivity, and protocol amendments.
Plan your study

Purpose-Built for Complex Clinical Trials

Unlike IRT modules bolted onto general-purpose EDC, Suvoda was designed from the ground up for protocols that punish vanilla systems — oncology with response-adaptive randomization, rare disease with stratified small cohorts, cell and gene therapy with chain-of-identity supply, and master protocols spanning multiple sub-studies. Configurability over adaptive randomization, dose-titration, kit and visit logic, and emergency unblinding workflows is what differentiates Suvoda from EDC-bundled IRT in real protocol negotiations between sponsors and vendors.

Suvoda IRT platform showing adaptive randomization and dose-titration workflows for complex oncology trials

Unified eConsent and eCOA

Suvoda's eConsent and eCOA modules complement IRT in a single sponsor-facing platform — meaningfully different from the alternative of integrating three best-of-breed vendors with three audit trails, three validation programmes, and three change-control regimes. For decentralized and hybrid designs in particular this matters: consent, assessment, and randomization meet at the subject visit, and a coherent platform reduces operational drag. The pattern aligns with FDA decentralized clinical trials guidance.

Suvoda unified eConsent and eCOA platform supporting decentralized and hybrid clinical trial designs

Built for 21 CFR Part 11 and ICH E6(R3)

Suvoda ships with the technical controls regulated sponsors expect — computer-generated audit trails, electronic signatures, configurable approval workflows, immutable versioning, and role-based access — aligned with 21 CFR Part 11, EU Annex 11, and ICH E6(R3) GCP. We deliver the validation framework — URS through UAT, periodic review, and SOPs — that turns those technical capabilities into a defensible, inspection-ready GxP study build.

Suvoda GxP compliance architecture with electronic signatures, audit trail, and role-based access controls

What We Deliver With Suvoda

Our Suvoda practice covers the full lifecycle — from initial study build and integration through AI-driven supply forecasting to ongoing compliance across global studies.

Study Build & Configuration

Design randomization schemas, dose-titration logic, IP supply rules, kit and visit logic, eConsent and eCOA configuration, and emergency unblinding workflows — all aligned with your protocol and operational model.

Plan study build

GxP Validation

Validate Suvoda study builds per GAMP 5 Second Edition. We deliver URS, risk assessment, UAT protocols, traceability matrices, SOPs, and periodic review aligned with FDA CSA principles and ICH E6(R3) GCP.

Validation details

AI & MCP Integration

Extend Suvoda with AI-driven supply forecasting, protocol amendment impact analysis, randomization analytics, and operational co-pilots — under compliance guardrails with auditable prompts and human approval.

AI integration

EDC, CTMS & Depot Integration

Connect Suvoda to Medidata Rave, Veeva Vault CDMS, Oracle Clinical One, Vault CTMS, depot ERP, and courier networks like Marken and World Courier. Validated integrations with full ALCOA+ traceability.

Discuss integrations

Protocol Amendments

Impact analysis, change request specification, configuration delta, regression UAT, and controlled production release for mid-study Suvoda amendments — including oncology adaptive design changes and master protocol additions.

Plan amendment

Managed Services & Optimization

Post-go-live study management, regression testing across Suvoda releases, periodic review, integration monitoring, supply forecasting tuning, and an AI capability roadmap. Fixed-fee retainer or embedded resources.

Managed services

Why Choose IntuitionLabs for Suvoda

We are not a generic IT integrator applying a one-size-fits-all playbook to clinical systems. IntuitionLabs combines deep clinical trial operations and GCP domain expertise with AI engineering capabilities most IRT implementation partners do not offer.

AI-First Clinical Operations

We build MCP-connected AI agents and forecasting models that turn Suvoda from operational plumbing into clinical-operations intelligence.

GCP & GxP DNA

ICH E6(R3), 21 CFR Part 11, GAMP 5, and ALCOA+ are core competencies — not certifications we picked up last quarter.

Cross-Platform Integration

We integrate Suvoda with EDC, CTMS, safety, depot, and analytics platforms — never standalone islands of clinical-trial data.

Suvoda Integration Ecosystem

🧪

Suvoda + EDC

Bidirectional integration between Suvoda IRT and your EDC — Medidata Rave, Veeva Vault CDMS, or Oracle Clinical One — so randomization, dispensation, and visit data flow without manual reconciliation. We design and validate the data contracts, error handling, and reconciliation needed for GCP confidence.

📋

Suvoda + CTMS

Connect Suvoda with Vault CTMS or other CTMS platforms so enrollment, site activation, and IP shipment data feed clinical operations dashboards in real time. Eliminates manual status updates that drift between systems and the inspection-ready trial master file.

🚚

Suvoda + Depot & Courier

Native and custom integrations with depot and courier networks (Marken, World Courier, Almac Clinical Services) for site shipments, returns, destruction records, and temperature-monitored chain of custody — automated and reconciled end to end.

🛡️

Suvoda + Safety

Stream blinded subject status and dispensation data into Oracle Argus, ArisGlobal LifeSphere, or Veeva Vault Safety so pharmacovigilance and case processing have current data. Code break workflows synchronize with safety case management without compromising blinding integrity.

📊

Suvoda + Analytics

Stream operational data from Suvoda to Snowflake, Databricks, or your clinical data hub for enrollment forecasting, supply optimization, and protocol-level dashboards. Validated extracts preserve metadata and audit context for downstream regulatory use.

🤖

Suvoda + AI (MCP)

Connect Claude and other LLMs to Suvoda via Model Context Protocol. AI-powered supply forecasting, protocol amendment impact analysis, randomization analytics, and operational co-pilots — within your compliance framework with auditable prompts and human review.

Today's business insights

Profitable growth in the AI solutions industry

Our CEO discusses how AI is transforming the pharmaceutical industry and shares key strategies for leveraging AI in drug discovery and development.

More insights on unlock profitable growth in ai solutions
Profitable growth in the AI solutions industry

Getting Started With Suvoda

Every Suvoda engagement starts with understanding your protocol, integration landscape, and regulatory context. Whether you are running your first oncology trial on Suvoda, standardising IRT across a global rare disease portfolio, or extending an existing deployment with AI capabilities, we tailor the approach to your therapeutic area and operational model.

Our team has implemented IRT and clinical systems for organizations ranging from clinical-stage biotechs to global pharma R&D networks. We bring the validation expertise and AI enablement capabilities that turn Suvoda from a study-build tool into a clinical-operations intelligence layer.

Engagement Models

  • Discovery Workshop — 2-day assessment of your protocol complexity, integration points, and Suvoda readiness
  • Study Build Project — Full Suvoda configuration including URS, randomization schema, supply logic, eConsent and eCOA, integrations, validation, and training (8-22 weeks)
  • AI Enablement Add-On — MCP integration, supply forecasting, amendment impact analysis, and operational co-pilots layered onto an existing Suvoda deployment
  • Managed Services — Ongoing amendments, regression testing, periodic review, and optimization retainer across the study lifecycle

Frequently Asked Questions

Suvoda is a clinical trial technology vendor whose flagship product is an Interactive Response Technology (IRT) platform — also marketed as a Randomization and Trial Supply Management (RTSM) system — used to randomize subjects, manage investigational product (IP) supply, and orchestrate logistics across complex global studies. Beyond IRT/RTSM, the Suvoda portfolio includes eConsent, electronic Clinical Outcome Assessments (eCOA), and integrated payments. The platform is purpose-built for oncology, rare disease, cell and gene therapy, and other high-complexity therapeutic areas where randomization schemas, dose adjustments, and drug supply logistics are not handled well by general-purpose EDC. IntuitionLabs implements, integrates, AI-enables, and validates Suvoda for sponsors and CROs running these protocols.
Suvoda, Medidata RTSM, Veeva Vault CDMS, and Calyx IRT all compete in the IRT/RTSM space, but they sit at different points on the complexity curve. Suvoda has built its reputation on oncology and rare disease — protocols with adaptive randomization, dose-titration arms, master protocols, and intricate IP supply rules — where its configurability outperforms more vanilla EDC-bundled offerings. Medidata RTSM is strong when the sponsor is already standardized on the Rave ecosystem, Veeva is emerging as a unified Vault-based option, and Calyx (formerly Parexel Informatics) competes on regulatory pedigree. We help sponsors run platform-agnostic evaluations grounded in real protocol requirements rather than vendor demos. Comparative context is captured in Applied Clinical Trials coverage of the IRT vendor landscape.
Suvoda is built to support 21 CFR Part 11, EU Annex 11, and ICH E6(R3) Good Clinical Practice through audit trails, electronic signatures, role-based access, and version-controlled study builds. As with any GxP platform, compliance is shared — Suvoda supplies the technical controls, the sponsor or CRO owns validated configuration, user procedures, and ongoing operational control. IntuitionLabs delivers the complete validation framework — User Requirements, risk assessment per ISPE GAMP 5 Second Edition, UAT scripts, traceability matrix, and a periodic review programme — so each Suvoda study build is inspection-ready in front of FDA, EMA, MHRA, and PMDA inspectors. See our full Suvoda GxP validation services.
RTSM systems handle two intertwined responsibilities: subject randomization (assigning each enrolled subject to a treatment arm using the protocol-defined schema) and trial supply management (ensuring the right investigational product is at the right depot, site, and visit at the right time, with the right kit and label). For modern protocols this includes adaptive randomization with response-driven allocation, dose-titration logic, cohort and dose-escalation gating, blinding maintenance through emergency unblinding workflows, expiry-aware kit allocation, and integration with depot and courier systems. The FDA adaptive designs guidance and ICH E9 statistical principles are foundational here. Suvoda was built specifically for protocols where these requirements are unusually demanding.
Integration is essential — Suvoda rarely lives in isolation. The platform exposes documented APIs and standard integration patterns for connecting to EDC systems such as Medidata Rave, Veeva Vault CDMS, and Oracle Clinical One; to CTMS like Veeva Vault CTMS; to safety platforms such as Oracle Argus and ArisGlobal LifeSphere; and to depot and courier providers including Marken, World Courier, and Almac Clinical Services. We design and validate these integrations end to end, with ALCOA+ traceability aligned with MHRA GxP data integrity guidance.
Suvoda itself is investing in AI-enabled features, but most sponsors want AI tightly integrated with their full clinical data fabric — not just one vendor silo. We build AI capabilities on top of Suvoda in three layers: (1) supply forecasting using historical kit consumption, enrollment curves, and expiry data to reduce both stockouts and wastage; (2) protocol amendment impact analysis that turns a redlined protocol into a Suvoda study-build change request; and (3) operational analytics co-pilots answering natural-language questions over randomization, IP, and visit data. All AI access goes through compliance guardrails — auditable prompts, model versioning, and human-in-the-loop approval for any production action. See our Suvoda AI integration service in detail.
A standard parallel-group Phase II or III study build on Suvoda typically completes in 8-14 weeks from URS sign-off to first-patient-in-ready UAT, depending on protocol complexity, blinding scheme, and the number of integrations. Adaptive oncology designs with response-adaptive randomization, master protocols, and complex IP logistics can run 14-22 weeks. We accelerate timelines through reusable study-build templates, parallel work on URS and configuration, automated UAT regression packs, and a risk-based validation approach aligned with GAMP 5 Second Edition and FDA Computer Software Assurance. Mid-study amendments — particularly in oncology — are a recurring need we plan for explicitly.
Yes. Suvoda's eConsent and eCOA modules are core enablers of decentralized clinical trial (DCT) and hybrid designs. We design study configurations that combine in-clinic and remote workflows, integrate with home health partners and direct-to-patient courier networks, and ensure data integrity across distributed touchpoints. The approach aligns with FDA decentralized clinical trials guidance and the EMA recommendation paper on decentralised elements. eConsent, eCOA, and IRT working as a coherent system is meaningfully different from gluing three vendors together.
Drug supply forecasting predicts how much investigational product needs to be at each site, depot, and country at each point in time — balancing expensive overage against the unacceptable risk of stockouts in active trials. The math draws on enrollment projections, randomization probabilities, dose-titration distributions, kit expiry, visit-window flexibility, and depot lead times. Suvoda provides the operational data; the forecasting model lives downstream. We build forecasting layers using statistical and AI approaches, validate them per GAMP 5 Category 5 software where they materially affect patient supply, and integrate them with depot ERP and courier systems. Real-world examples and pitfalls are well documented in Applied Clinical Trials.
Yes — protocol amendments are an operational reality, particularly in oncology and rare disease. Our amendment delivery process covers impact analysis on the existing Suvoda study build, change request specification, configuration changes, regression and delta UAT, controlled release into the production study, and updated validation evidence and traceability. We work in close coordination with the sponsor's clinical operations, regulatory, and supply functions because an IRT amendment is rarely isolated — it usually touches randomization, supply, and possibly eCOA visit schedules simultaneously. The change control framework is aligned with GAMP 5 and ICH Q9(R1) quality risk management.
Oncology is the centre of gravity for Suvoda — adaptive randomization, dose-titration, dose-escalation cohorts, basket and umbrella designs, and complex stratification schemas are routine configurations rather than edge cases. The platform handles response-adaptive allocation, Bayesian decision rules feeding next-cohort decisions, and master protocols where a shared randomization framework spans multiple sub-studies. Configuration depth is meaningful — we've seen sponsors choose Suvoda specifically because their previous IRT could not safely express their oncology protocol. The statistical foundation is documented in ICH E9, the E9(R1) estimands addendum, and the FDA master protocols guidance.
Yes. After go-live, our managed services cover study-build amendments and change control, integration monitoring, periodic review and re-qualification per GAMP 5, drug supply forecasting tuning, and an AI capability roadmap that grows platform value across the study lifecycle. We deliver these as a fixed-fee retainer or as embedded resources alongside your clinical operations, statistics, and supply teams. Learn more about our managed services.
Emergency unblinding is one of the highest-risk workflows in any IRT — it must be available 24/7 to investigators, must execute reliably for legitimate medical emergencies, and must be auditable and tightly controlled to preserve trial integrity. Suvoda provides configurable emergency code break workflows including stepped authorization, automated notifications to the sponsor, audit trail capture of the requesting investigator and stated reason, and immediate randomization-list lock-down on broken codes. We validate these workflows with explicit negative tests — what happens when a code break is attempted by an unauthorized user, what happens during a network partition — aligned with ICH E6(R3) GCP expectations for trial integrity.
Suvoda partners with sponsors directly and with major CROs that run trials on their behalf. Most sponsors blend Suvoda's own study-build services, internal clinical systems teams, and a specialist consultancy depending on workload mix and complexity. IntuitionLabs differentiates by combining hands-on Suvoda configuration and validation with the AI engineering capability needed to extend the platform — including Model Context Protocol (MCP) integrations, AI-driven supply forecasting, and operational analytics co-pilots. We are a pharma-focused AI consulting and software development firm, not a generalist SI, so the GCP rigour and clinical-systems depth come built-in.
We run a structured evaluation that maps your portfolio's protocol complexity, integration landscape, and operational model against Suvoda, Medidata RTSM, Calyx, Veeva CDMS, and other contenders. The output is a scored matrix grounded in your real protocols — adaptive designs, dose-titration, master protocols, eConsent and eCOA needs, depot footprint — rather than vendor marketing. For sponsors with heavy oncology or rare disease pipelines, Suvoda is frequently the right answer; for portfolios dominated by simple parallel-group designs already in the Rave or Vault ecosystem, the analysis often tips the other way. We are platform-agnostic and routinely advise sponsors to pick the system that best fits the work, then we implement and validate it.
Ready to Modernise Your Clinical Trial Operations?
Ready to Modernise Your Clinical Trial Operations? image

Ready to Modernise Your Clinical Trial Operations?

Book a discovery session to explore how Suvoda IRT, RTSM, eConsent, and eCOA — implemented, validated, and AI-enhanced by IntuitionLabs — can transform oncology, rare disease, and decentralized trial operations across your pipeline.

Book a Meeting

© 2026 IntuitionLabs. All rights reserved.

Privacy PolicyTerms of ServiceBook Meeting